31
7. Dib SA, Russo EMK, Chacra AR. Tratado de endocrinologia clínica. São Paulo:
Ed. Rocca; 1992.
8. Wetzler C, Kampfer H, Stallmeyer B, Pfeilschifter J, Frank S. 2000. Large and
sustained induction of chemokines during impaired wound healing in the genetically
diabetic mouse: prolonged persistence of neutrophils and macrophages during the
late phase of repair. J Invest Dermatol 115:245-253.
9. Gooch HL, Hale JE, Fujioka H, Balian G,. Hurwitz SR. 2000. Alterations of
cartilage and collagen expression during fracture healing in experimental diabetes.
Connect Tissue Res 41:81-91.
10. He H, Liu R, Desta T, Leone C, Gerstenfeld LC, Graves DT. 2004. Diabetes causes
decreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of
osteoblastic cells in bacteria stimulated bone loss. Endocrinology 145:447-452.
11. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R,
Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E,
Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J,
Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates
osteoclast differentiation and activation. Cell 93:165-176.
12. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S,
Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K,
Udagawa N, Takahashi N, Suda T. 1998. Osteoclast differentiation factor is a ligand
for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to
TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597-3602.
13. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation.
Nature 423:337-342.